Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis : a systematic review literature by M. Benucci et al.
Hindawi Publishing Corporation
International Journal of Rheumatology
Volume 2011, Article ID 845496, 6 pages
doi:10.1155/2011/845496
Review Article
Cost Effectiveness Analysis of Disease-Modifying Antirheumatic
Drugs in Rheumatoid Arthritis. A Systematic Review Literature
Maurizio Benucci,1 Gianantonio Saviola,2 Mariangela Manfredi,3
Piercarlo Sarzi-Puttini,4 and Fabiola Atzeni4, 5
1Rheumatology Unit Department of Internal Medicine, Hospital S. Giovanni di Dio, Azienda Sanitaria di Firenze,
50143 Florence, Italy
2Rheumatology and Rehabilitation Unit, Salvatore Maugeri Foundation IRCCS, 46042 Mantua, Italy
3 Immunology and Allergology Laboratory Unit, Hospital S. Giovanni di Dio, Azienda Sanitaria di Firenze, 50143 Florence, Italy
4Rheumatology Unit, Sacco University Hospital, 20127 Milan, Italy
5Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London,
London E14DG, UK
Correspondence should be addressed to Maurizio Benucci, maubenucci@tiscali.it
Received 1 March 2011; Revised 3 August 2011; Accepted 8 September 2011
Academic Editor: Ronald F. van Vollenhoven
Copyright © 2011 Maurizio Benucci et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The cost eﬀectiveness of treatments that have changed the “natural history” of a chronic progressive disease needs to be evaluated
over the long term. Disease-modifying antirheumatic drugs (DMARDs) are the standard treatment of rheumatoid arthritis (RA)
and should be started as early as possible. A number of studies have shown that they are eﬀective in improving disease activity and
function, and in joint damage. Our review was focused on revision and critical evaluation of the studies including the literature
on cost eﬀectiveness of DMARDs (cyclosporine A, sulphasalazine, leflunomide, and methotrexate). The European League Against
Rheumatism (EULAR) recommendations showed that traditional DMARDs are cost eﬀective at the time of disease onset. They
are less expensive than biological DMARDs and can be useful in controlling disease activity in early RA.
1. Introduction
Rheumatoid Arthritis(RA) aﬀects about 272,000 Italian pa-
tients. Population data have showm that the prevalence of
RA in Italy is 0.46% [1]. In 2002, it was estimated that the
socioeconomic cost of RA in Italy was 1600 million euros
(1210 million for indirect social costs and 380 million for
direct medical costs). The calculated average annual cost for
each patient varies significantly depending on disease sever-
ity and correlates with the Health Assessment Question-
naire Disability Index (HAQ-DI) and American College of
Rheumatology (ACR) Steinbrocker criteria, from C3,718.3
in class I to C22,946 in class IV [2].
The economic impact of RA is substantial in terms of
direct, indirect, and intangible costs. Direct costs are those
related to RA, such as medications, clinic visits, hospitalisa-
tions, aids, devices, and transportation; indirect costs include
the costs incurred by society as a result of lost productivity
and reduced patient and family incomes: intangible costs are
those arising from the reduced quality of life and premature
mortality. As RA is a chronic inflammatory joint disease that
mainly aﬀects people of working age, its costs are consider-
able [3].
The cost eﬀectiveness of treatments that can change the
“natural history” of a chronic progressive disease has to be
evaluated over the long term using models that allow vary-
ing the assumptions of treatment continuation and long-
term eﬀects and assess the uncertainty concerning results,
including those from the clinical trials. There are many
approaches to modelling costs and outcomes and assessing
cost eﬀectiveness, including the use of disease models based
on epidemiological data in which costs and the quality of
life (utility) are related to the degree of disease severity and
progression [4]. In models of RA, disease severity is based
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on functional status as measured by the HAQ, and outcomes
are expressed as quality-adjusted life years (QALYs) [5]. The
cost eﬀectiveness estimates are based on the concept that
treatment will prevent progression to the next level(s) of dis-
ease severity or will take longer time to progress, thus avoid-
ing or delaying the high costs and low utility levels associated
with more severe disease [6].
Recent Italian population data have shown that the prev-
alence of RA has increased to 0.49% [7], in line with the find-
ings of epidemiological studies carried out in the United State
(US) [8]. The incidence of new cases is increasing [9], but it
has not been followed by an increase in the use of biological
therapy, which was prescribed for only 6.3% of RA patients
in 2009 [10].
The purpose of this paper is to review and critically assess
the existing literature on the cost eﬀectiveness of traditional
DMARDs.
2. Cost Effectiveness of DMARDs in RA
When considering RA drug therapy, a number of factors
seem to predict the cost-eﬀectiveness analysis. First of all,
disability is the major determinant of cost, and so drugs that
slow joint destruction and delay the onset of disability may
therefore be cost eﬀective. Secondly, the costs related to ad-
verse events form a major portion of the real drug costs;
therefore, a drug with a good safety profile will probably be
more cost eﬀective than one that shows similar eﬃcacy but
has more side eﬀects. Finally, it must be remembered that
RA drug therapy must be eﬃcacious and safe over the long
term.
DMARDs are the standard treatment of RA and should
be started as early as possible. A number of studies have
shown that they are eﬀective in improving disease activity
and function, and delaying joint damage. However, there are
not many economic analyses of DMARD treatment in RA
[11].
3. Methods
To collect and review the evidence, we performed a system-
atic literature review (SLR) aiming at economic evaluations
of RA treatment. The search used Medline, Embase, and
Cochrane databases to identify publications concerning eco-
nomic aspects of adult RA, published in English from the
year of database inception until June 2011. We evaluated
the main cost eﬀectiveness studies of the DMARDs currently
used in RA using the search words DMARDs (cyclosporine
A, sulphasalazine, leflunomide, and methotrexate), cost ef-
fectiveness analysis, and rheumatoid arthritis.
The selected papers included randomised controlled
trials (RCTs) and observational studies (prospective and ret-
rospective cohort and case-control studies).
In addition, we hand-searched abstracts presented at the
2007 and 2008 ACR and EULAR conferences.
Where possible, we collected cost eﬀectiveness results
as an incremental cost-eﬀectiveness ratio (ICER), the most
frequently reported outcome in cost-eﬀectiveness analyses
(CEAs) reflecting the additional cost per QALY gained by a
particular treatment. Although the exact societal willingness-
to-pay (WTP) threshold remains controversial, based on
ICERs of other commonly accepted medical interventions,
we defined ICERs below US $50.000–100.000 or £30.000 or
C50.000 per QALY, as being cost eﬀective [12].
4. Results
We identify in PubMed database using the following words
DMARDs (cyclosporine A, sulphasalazine, leflunomide, and
methotrexate), cost eﬀectiveness analysis, and rheumatoid
arthritis a total of 86 studies.
Out of 86 studies, 33 were excluded due to the compari-
son between cost-eﬀectiveness analysis of DMARDs and anti
TNF alpha agents (6 studies on etanercept, 3 on adalimumab,
7 on infliximab, and 1 on certolizumab pegol).
Furthermore, we excluded a total of 6 studies because
they were focused on comparison between cost-eﬀectiveness
analysis of DMARDs and other biological agents (2 studies
on anakinra, 2 on abatacept, 1 on tocilizumab, and another
one on rituximab).
On the basis of selection, we evaluated one cost-effect-
iveness meta-analysis for cyclosporine A (CyA), one paper of
step-down therapy with sulphasalazine (SSZ), three different
papers that compared leflunomide (LNF) alone or against
other DMARDs (SSZ andmethotrexate), and five papers that
evaluated methotrexate in monotherapy, in combination
with hydroxychloroquine (HCQ), SSZ, and against LNF. Fur-
thermore, we considered the three recent papers that com-
pared the use of DMARDs in particular methotrexate (MTX)
in early or long-standing RA evaluated with biological anti-
TNF alpha inhibitors (Table 1).
4.1. Cyclosporine A. The cost eﬀectiveness of CyA in the
treatment of RA has been investigated in a meta-analysis of
five randomised, controlled, and parallel-group clinical trials
that used a fixed eﬀects model to calculate treatment eﬀects
and incremental economic analyses from the perspectives of
society and the Ontario Ministry of Health (MoH). Com-
parisons were made with placebo, and there were two head-
to-head comparisons. The total treatment cost for a typical
patient was calculated using a modified intention-to-treat
approach modelled over one year. CyA led to a ≥25% im-
provement in tender joint counts in 35% of the patients
against 17% of the patients receiving placebo; there was no
significant diﬀerence between CyA and azathioprine (AZA)
or D-penicillamina (D-Pen). From the perspective of the
Ontario MoH, the annual incremental cost of achieving the
same level of improvement was $1,473 between CyA and
AZA, and $1,618 between CyA and D-Pen; the annual incre-
mental cost eﬀectiveness ratio per patient improved between
CyA and placebo was $11,547. From the point of view of
society, the incremental cost of CyA was $2,886 over AZA,
and $3,731 over D-Pen, and the annual incremental cost
eﬀectiveness ratio against placebo was $20,698 [13].
4.2. Sulphasalazine. The cost eﬀectiveness and cost utility of
early intervention in RA patients have been investigated by
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Table 1: Studies on cost eﬀectiveness analysis of DMARDs in rheumatoid arthritis.
Authors and years of
publication
Type of the drugs Countries Overall time
Evaluation’s
model
Outcomes Cost/Eﬀective/Ratio
Anis et al. 1996 [13]
CyA versus AZA
versus D-Pen
Canada 12 months ITT ICER 20,698$
Verhoeven et al. 1998
[14]
SSZ versus COMBO Netherland 56 weeks QALY 6511 versus 5519$
Maetzel et al. 2002
[15, 16]
LNF Canada 12 months ACR 20 QALY 54229$
Maetzel et al. 2002
[15, 16]
LNF versus MTX Canada 12 months ACR 20 QALY 3853$
Kobelt et al. 2002 [4, 17]
LNF versus MTX
versus SSZ
UK 15 years Markov QALY
35855 versus 44988
versus 37731£
Bruns et al. 2000 [18]
MTX versus ETN
versus MTX + ETN
versus MTX + CyA
versus HCQ +
MTX + SSZ
USA 6 months
ACR 20
ACR 70WN
Tree model 1100 versus 1500$
Choi et al. 2002 [19]
MTX versus ETN
versus LNF versus
SSZ
USA 6 months
ACR 20
ACR 70WN
Tree model 900 versus 1500$
Osiri et al. 2007 [20]
MTX versus
DMARDs
Thailand 1 year HAQ ICER 834 versus 2061$
Scha¨dlich et al. 2005 [21] MTX versus LFN Germany 1 year HFAQ Tree 708 versus 2010C
Korthals-De Bos et al.
2004 [22]
COBRA versus SSZ Netherland 28 weeks HAQ QALY 2578 versus 3638$
Hartman et al. 2004 [23]
MTX versus MTX +
folic acid
Netherland 48 weeks EuroQol QALY 1398 versus 1776$
Schipper et al. 2011 [32]
MTX versus MTX +
LNF versus MTX +
TNF
Netherland 5 years Markov QALY 16620 versus 17574$
CyA: cyclosporine A; HCQ: hydroxychloroquine; TNF: tumour necrosis factor; LNF: leflunomide; MTX: methotrexate; ETN: etanercept; SSZ: sulphasalazine;
DMARDs: disease modifying antirheumatic drugs; ACR: American College of Rheumatology; HAQ: health assessment questionnaire; ITT: intention to treat;
QALY: quality-adjusted life years; ICER: incremental cost-eﬀectiveness ratio HFAQ: Hannover Functional Ability Questionnaire; UK: United Kingdom; USA:
Unite States of America.
comparing combined step-down prednisolone, MTX, and
SSZ (76 patients) with SSZ alone (78 patients). The mean
total cost per patient in the first 56 weeks of follow-up was
$5519 for the combined treatment and $6511 for treatment
with SSZ alone (P = 0.37). Outpatient, inpatient and non-
health care each contributed about one-third to the total
cost. The combined treatment group appeared to generate
savings in terms of the duration of hospitalisation because of
RA, nonprotocol drugs, and the costs of home help although
protocol drugs and monitoring were slightly more expensive.
Clinical, radiographic, and functional outcomes significantly
favoured combined treatment at week 28 (and radiographic
outcome also at week 56). The utility scores also favoured
combined treatment [14].
4.3. Leflunomide. A DMARD sequence including LFN has
been compared with one excluding it using a 5-year simu-
lation model in which the patients cycle through diﬀerent
treatment regimens. The data were obtained by means of a
systematic review of the literature (drug withdrawal rates, the
number and type of adverse events, and ACR 20% responder
status) and separately surveyed (the choice of DMARD
sequence, the management of adverse events). The costs of
adverse event management were calculated using the Ontario
Schedule of Benefits, and monitoring of costs was calculated
according to oﬃcial Canadian product monograph recom-
mendations. Utilities (as measured by the standard gamble
(SG) and rating scale (RS) techniques) were obtained from
482 patients who participated in a 1-year randomised con-
trolled trial comparing LFN,MTX, and placebo. Adding LFN
to a conventional DMARD strategy increased 5-year man-
agement costs by $1,231, which leads to a cost-eﬀectiveness
ratio of $13,096 per additional year of response to treatment,
and cost-utility ratios of $54,229 (RS) and $71,988 (SG)
per QALY gained [15]. The annualised total RA- or drug-
related costs for LNF, MTX, and placebo were, respectively,
$1761, $1280, and $1324, and the medical care costs were,
respectively, $753, $620, and $167 (Canadian dollars) (all
costs excluding drug acquisition and monitoring costs).
The estimated annual drug acquisition/routine monitoring
costs were 3853/483 Canadian dollars for LNF and 258/599
Canadian dollars for methotrexate. The diﬀerences between
the overall costs (excluding drug acquisition and monitoring
costs) andmedical care costs were not statistically significant.
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The cost of treating patients with LNF was significantly
higher than that of treating them with methotrexate when
drug acquisition and monitoring costs were included (P <
0.0001) [16].
A Markov model has been constructed using the health
states defined by the HAQ score. This model is based on a
cohort of patients with recently diagnosed definite RA who
were followed for up to 15 years by nine rheumatology clinics
in the United Kingdom (UK). The treatment eﬀect was
calculated on the basis of clinical trials comparing LFN and
MTX (one international and one US trial) or sulphasalazine
(one international trial). Using the US trial, LFN had slightly
lower costs and better eﬀects than MTX (£44,017 and 4,307
QALYs versus £44,988 and 4.158 QALYs), but this was
reversed when using international trial (£36,351 and 4,372
QALYs versus £34,070 and 4.487 QALYs). In comparison
with sulphasalazine, the cost of using LEF was slightly lower,
and there was an increase in QALYs (£35,855 and 3.896
QALYs versus £36,731 and 3.721 QALYs). The reason for
the diﬀerent results when using the two trials comparing
LFN with MTX was possibly that the MTX patients in the
US trial were also treated with folic acid, whereas folate
supplementation was not mandatory in the international
trial; this may have reduced the eﬀectiveness of MTX. In
comparison with sulphasalazine, the use of LFN appears to
be cost eﬀective in the UK [17].
4.4. Methotrexate. A cost eﬀectiveness analysis has been
made using a decision model with a time horizon of six
months and comparing six treatment options for patients
with MTX-resistant RA: (1) etanercept + MTX, (2) etaner-
cept monotherapy, (3) CyA + MTX, (4) triple therapy (hy-
droxychloroquine, sulphasalazine, and MTX), (5) the con-
tinuation of MTX monotherapy, and (6) no second-line
agent. Twomeasures of eﬀectiveness based on published clin-
ical trial data were used: the ACR 20% response criteria (ACR
20), and a weighted average of the proportion of patients
achieving ACR 70, ACR 50, and ACR 20 responses (ACR 70
weighted response (ACR 70WR)). The results showed that
MTX therapy for MTX-naive RA patients cost $1,100 per
ACR 20 outcome and $1,500 per ACR 70WR, in comparison
with no second-line agent. The least expensive option was
triple therapy, which cost 1.3 times more per patient with
an ACR 20 outcome ($1,500/ACR 20) and 2.1 times more
per ACR 70WR ($3,100/ACR 70WR) than MTX therapy
in MTX-naive RA patients. The analysis indicates that if
15mg/week MTX is cost eﬀective for achieving ACR 20 or
ACR 70WR in MTX-naive RA patients over a 6-month
period, it is likely that the triple therapy is also cost eﬀective
in patients with MTX-resistant RA [18].
The same authors inMTX-naı¨ve RA patients showed that
MTX is cost eﬀective (cost saving versus the no-second line
agent option) for achieving ACR 20 or ACR 70WR over a 6-
month period. However, based on available data, the relative
cost eﬀectiveness of SSZ and MTX cannot be determined
with reasonable certainty although SSZ therapy seems to
be cost eﬀective as MTX (cost saving) for achieving ACR
outcomes over a 6-month period [19].
Data concerning disease activity, functional status, and
society costs have been collected from a 1-year cohort of
152 patients with RA receiving at least one DMARD for six
months. Treatment with MTX + antimalarials (AMs) would
save asmuch as US $834 per 1 unit (U) of HAQ improvement
per year in comparison with AMs alone. Other DMARD
options with MTX or LFN were more expensive than AMs
but were more eﬃcacious and considered cost eﬀective.
Treatment with these DMARDs would incur additional costs
of US $625–2,061 per 1U of HAQ improvement per year.
DMARD options without MTX were not cost eﬀective [20].
An analysis from the perspective of society has beenmade
in Germany using a modelling approach based on the sec-
ondary analysis of existing data and on data obtained from
a sample of 583 patients included in the German rheuma-
tological database of 1998. Functional capacity was defined
on the basis of Hannover Functional Ability Questionnaire
(HFAQ) scores, and the costs were calculated on the basis of
resource use and the patients’ working capacity. The average
total direct costs (1998–2001 values) per patient per year for
continuous treatment with the selected DMARDs, including
purchase costs and the monitoring and treatment of adverse
drug reactions (ADRs), were highest for intramuscular gold
(sodium aurothiomalate) (C2106; C1 H $US 0.91, the av-
erage of the period 2000-2001) followed by LFN (C2010),
AZA (C1878), sulphasalazine (C1190), oral MTX (C708),
and lowest for the AMs: chloroquine/hydroxychloroquine
(C684) [21].
The eﬀect of indirect costs for patients with early RA in
the COBRA trial (Combinatie therapie Bij Reumatoide Artri-
tis) on the cost eﬀectiveness of the treatment with predni-
solone, MTX, and SSZ (the COBRA combination) or with
SSZ alone has been shown that, in the first 28 weeks, indirect
costs per patient were US$2,578 for COBRA and US$3,638
for SSZ (P = 0.09); the total costs were, respectively, $5,931
and $7,853 (P < 0.05) [22].
A randomized-double blind-placebo-controlled trial on
cost eﬀectiveness of folic or folinic acid supplementation in
RA patients treated with MTX using EuroQol questionnaire
to assess the QALY showed no significant diﬀerences among
patients taking folic or acid folic supplementation or placebo
over a 6-month followup [23].
5. Discussion
Given the increase in health-related costs and limited health
care resources, assessing the cost eﬀectiveness of medical
procedures is gaining considerable importance in the field
of rheumatology; particularly, as the annual therapy costs of
using TNF-blocking agents such as etanercept and infliximab
(C17,000–21,000) are much higher than those of using
DMARDs in the treatment of RA [24]. TNF inhibitors are
currently considered both eﬀective and cost eﬀective in pa-
tients with active RA, especially in patients who have not
fully responded to MTX, but the data suggest that, in routine
clinical practice, they provide only modest incremental
benefits over the best conventional therapy. If confirmed,
these observational findings suggest that the economic issue
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underpinning the widespread use of TNF inhibitors in es-
tablished RA is unsustainable [25].
In a previous real-life postmarket observational study, we
demonstrated that etanercept plus MTX was cost eﬀective
with a QALY lower than the acceptable threshold of C50,000,
andMTXwas more cost eﬀective than LFN [26]. The eﬃcacy
of LFN is comparable with that of SSZ and MTX, but LFN is
more expensive than most DMARDs, and costs about £400
per year more than SSZ [27].
Three management strategies have been compared: a
symptomatic or “pyramid” strategy starting with nonster-
oidal anti-inflammatory drugs, patient education, pain man-
agement, and low-dose glucocorticoids, then switching non-
responders to DMARDs after one year; early DMARD thera-
py with MTX; early therapy with biological agents andMTX.
When the cost of very early intervention was factored in,
the cost eﬀectiveness ratio of the early DMARD strategy was
$4849 per QALY (95% CI: $0–16,354 per QALY) in compar-
ison with the pyramid strategy, whereas the benefits gained
using the early biological strategy came at a substantially
increased cost. Very early intervention with conventional
DMARDs is cost eﬀective, whereas the cost eﬀectiveness of
very early intervention with biological agents remains uncer-
tain [28].
A systematic review of 18 papers has shown that bi-
ological agent/DMARDs sequences are cost eﬀective in
DMARD-naı¨ve patients for the threshold Canada dollars
(CAD) 100,000/QALY. In the patients failing on combined
MTX therapy or sequentially administered DMARDs, cost-
eﬀectiveness ratios (ICERs) were well above CAD 50,000/
QALY, and 40% were below CAD 100,000/QALY. The most
cost eﬀective approach seems to be DMARD treatment early
in the course of RA, then moving to a DMARD sequence
in the case of a nonresponse, and finally adding a biological
drug if the nonresponse continues [29].
A review of the cost eﬀectiveness of RA treatments and
the clinical recommendations of EULAR has shown that
DMARDs are cost eﬀective at disease onset, that is, that
the merits of treatment outweigh its costs. If DMARDs fail,
therapeutic escalation with TNF inhibitors is cost eﬀective
when standard-dosing regimens are used. If TNF inhibitors
fail, rituximab or abatacept is cost eﬀective. There is little eco-
nomic evidence for switching TNF inhibitors [30]. MTX and
biological agents have been found to be similarly eﬀective as
measured by ACR and EULAR response criteria, including
clinical remission although folic acid supplementation may
have reduced the eﬃcacy of MTX by interfering with its
mechanism of action.
Nonetheless, all of the trials have confirmed the surpris-
ingly good performance of MTX in comparison with biolog-
ical agents [31].
A validated Markov model was used to evaluate the cost
eﬀectiveness of all three strategies, while a daily practice data
from two diﬀerent cohorts was used to determine the effect-
iveness of the strategies. Patients treated according to these
strategies were matched for baseline DAS-28. The expected
costs, the QALYs, and the incremental cost per QALY
gained over a 5-year time were calculated using a Monte
Carlo simulation, from health-care and societal perspectives.
Starting with following combination therapy (MTX plus
LFN or plus anti-TNF) is more expensive than starting with
MTX in monotherapy. Furthermore, starting with anti-TNF
therapy is far more expensive than starting with MTX in
monotherapy [32].
Conventional DMARDs are much less expensive than
biological DMARDs and, in many cases, can lead to similar
control of disease activity, particularly in early RA. The goal
for all patients should be to obtain remission or at least a low
level of disease activity using the most cost-eﬀective therapy
possible.
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